Luc Gérard Berthiaume
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Luc Gérard Berthiaume has a total of 198 co-authors. Here are the top co-authors by number of shared publications:
- Aishwarya Iyer
Division of Dermatology, Department of Medicine, and
32 shared publications - Cassidy Ekstrom
Department of Cell Biology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada
32 shared publications - Erwan Beauchamp
Pacylex Pharmaceuticals Inc., Edmonton, Canada
32 shared publications - Jay M. Gamma
Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada
32 shared publications - Jean C. Y. Wang
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
32 shared publications - John R. Mackey
Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
32 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
FIgure S1 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S1: NMT1 and NMT2 have distinct expression patterns. NMT1 is consistently expressed in ∼1 400 CCLE cell lines and ∼11 000 TCGA patient samples. NMT2 is more variable and entirely absent in some cells. Expression measured by RNASeq and expressed as Log2(TPM+1). Data extracted from DepMap (CCLE, Expression Public 23Q2) and TCGA (via TCGABiolinks).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFIgure S1 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S1: NMT1 and NMT2 have distinct expression patterns. NMT1 is consistently expressed in ∼1 400 CCLE cell lines and ∼11 000 TCGA patient samples. NMT2 is more variable and entirely absent in some cells. Expression measured by RNASeq and expressed as Log2(TPM+1). Data extracted from DepMap (CCLE, Expression Public 23Q2) and TCGA (via TCGABiolinks).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S5: MISS-54 Scores Categorized by AML Risk Category TCGA-LAML patients were separated into groups by ELN2022 risk classification (A) or TCGA-LAML molecular risk category (B) and MISS-54 scores of groups compared by one-way ANOVA. No significant differences were found between groups.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S5: MISS-54 Scores Categorized by AML Risk Category TCGA-LAML patients were separated into groups by ELN2022 risk classification (A) or TCGA-LAML molecular risk category (B) and MISS-54 scores of groups compared by one-way ANOVA. No significant differences were found between groups.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Figure S7: SFKs respond similarly to zelenirstat. AML cell lines were pre-treated with 1µM zelenirstat for 48 hours, then stimulated with 100 ng/mL SCF & FL. Levels of indicated Src-family kinases were analyzed by western blot.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Figure S7: SFKs respond similarly to zelenirstat. AML cell lines were pre-treated with 1µM zelenirstat for 48 hours, then stimulated with 100 ng/mL SCF & FL. Levels of indicated Src-family kinases were analyzed by western blot.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S3: NMT2 is associated with overall survival in the GSE37642 dataset: Patients in the GSE37642 dataset were separated into quartiles based on NMT2 expression, and overall survival analyzed via Kaplan-Meier plots. Curves were compared by log-rank test.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S3: NMT2 is associated with overall survival in the GSE37642 dataset: Patients in the GSE37642 dataset were separated into quartiles based on NMT2 expression, and overall survival analyzed via Kaplan-Meier plots. Curves were compared by log-rank test.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S11: Zelenirstat reduces glycolytic rate in AML cells. MV-4-11 (A-B) and U937 (C-D) cells were incubated with zelenirstat for 48 hours, then extracellular acidification assessed using an Aglient Seahorse and Glycolytic Rate Assay kit.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S11: Zelenirstat reduces glycolytic rate in AML cells. MV-4-11 (A-B) and U937 (C-D) cells were incubated with zelenirstat for 48 hours, then extracellular acidification assessed using an Aglient Seahorse and Glycolytic Rate Assay kit.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S6: Zelenirstat causes manageable weight loss in mice. Body weight of mice in xenograft experiments fig3C (A) and fig3D (B). High-dose zelenirstat caused weight loss that was rapidly recovered after cessation of treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S6: Zelenirstat causes manageable weight loss in mice. Body weight of mice in xenograft experiments fig3C (A) and fig3D (B). High-dose zelenirstat caused weight loss that was rapidly recovered after cessation of treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S14: Zelenirstat shows promising synergy with venetoclax. AML cell lines were screened for synergy between zelenirstat and venetoclax using Horizon’s Combination Profiling platform. Isobolograms of (A) MV-4-11 and (B) KG-1 cell lines of zelenirstat and venetoclax combination therapy. Trendlines below additivity line indicate synergy. (C) Synergy scores of AML cell lines in combination with venetoclax. Synergy scores indicate growth inhibition in excess of additive effects.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S14: Zelenirstat shows promising synergy with venetoclax. AML cell lines were screened for synergy between zelenirstat and venetoclax using Horizon’s Combination Profiling platform. Isobolograms of (A) MV-4-11 and (B) KG-1 cell lines of zelenirstat and venetoclax combination therapy. Trendlines below additivity line indicate synergy. (C) Synergy scores of AML cell lines in combination with venetoclax. Synergy scores indicate growth inhibition in excess of additive effects.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Figure S8: Zelenirstat disrupts signalling in AML. U937 and KG-1 cells were incubated with zelenirstat for 48 hours, stimulated with 100 ng/mL FL & SCF, then lysed. Lysates were probed for HCK, phosphorylated SFKs, and phosphorylated Stat5 by western blotting. Band intensity was determined using Image Studio Lite, and each sample normalized to actin. Differences between treatment groups determined using one-way ANOVA.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Figure S8: Zelenirstat disrupts signalling in AML. U937 and KG-1 cells were incubated with zelenirstat for 48 hours, stimulated with 100 ng/mL FL & SCF, then lysed. Lysates were probed for HCK, phosphorylated SFKs, and phosphorylated Stat5 by western blotting. Band intensity was determined using Image Studio Lite, and each sample normalized to actin. Differences between treatment groups determined using one-way ANOVA.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S9: Zelenirstat causes ER stress and Apoptosis in AML Cell Lines U937, and KG-1 cell lines were incubated with zelenirstat for up to 72 hours, then lysed and proteins analyzed by western blot. Representative blots of 3 biological replicates. Band intensity was determined using Image Studio Lite, and each sample normalized to actin. Differences between treatment groups determined using one-way ANOVA.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Figure S9: Zelenirstat causes ER stress and Apoptosis in AML Cell Lines U937, and KG-1 cell lines were incubated with zelenirstat for up to 72 hours, then lysed and proteins analyzed by western blot. Representative blots of 3 biological replicates. Band intensity was determined using Image Studio Lite, and each sample normalized to actin. Differences between treatment groups determined using one-way ANOVA.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Data from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells
Supplementary Data from Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells